OOIR: Observatory of International Research

Papers

(The H4-Index of Neuro-Oncology is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary	4362
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017	1119
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	756
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions	518
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019	364
EANO guideline on the diagnosis and management of meningiomas	224
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter	155
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial	136
Epidemiology of brain metastases and leptomeningeal disease	118
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1–2 signaling	110
Fully automated hybrid approach to predict theIDHmutation status of gliomas via deep learning and radiomics	110
The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications	104
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas	102
Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma	98
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis	89
CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018	82
Associations of meningioma molecular subgroup and tumor recurrence	78
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial	77
Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group	75
Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics	73
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR	73
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial	72
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons	72
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification	72
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma	71

A molecularly integrated grade for meningioma	70
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study	65
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors	65
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)	63
Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance	63
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)	62
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors	62
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)	61
EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults	60
Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery	60
Neuro-oncology management during the COVID-19 pandemic with a focus on WHO grades III and IV gliomas	60
Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma	59
Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity	58
Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas	58
Brain metastasis detection using machine learning: a systematic review and meta-analysis	58
Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank	57
Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification	57
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma	57
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors	56
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors	56
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein	56
Clinical trial of proton craniospinal irradiation for leptomeningeal metastases	55
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design	54
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study	54
Artificial intelligence neuropathologist for glioma classification using deep learning on hematoxylin and eosin stained slide images and molecular markers	53
A serum-based DNA methylation assay provides accurate detection of glioma	53
Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on “Head Start” III: a multi-institutional, prospective clinical trial	52
The evolution of the cancer stem cell state in glioblastoma: emerging insights into the next generation of functional interactions	52